Pulmonology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Churg–Strauss angiitis
Best Practice & Research: Clinical Rheumatology, 06/30/09

Sinico RA et al. – Churg–Strauss angiitis or syndrome (CSA) is defined as an eosinophil-rich and granulomatous inflammation involving the respiratory tract, coupled with necrotising vasculitis affecting small- to medium-sized vessels, and is associated with asthma and eosinophilia. This review article outlines the diagnosis and classification and treatment available for this disease.

It is usually classified among the ANCA-associated systemic vasculitides (AASVs)
However, ANCA status was shown to segregate with clinical phenotype in two recent studies
ANCA-positive pts were more likely to have disease manifestations associated with small-vessel vasculitis
Whereas ANCA-negative cases were more likely to have cardiac and lung involvement
Preliminary results suggest that ANCA-positive and ANCA-negative pts also might have a different genetic background
Corticosteroids remain the initial treatment of CSA
Addition of cyclophosphamide is indicated in treatment of pts with poor-prognosis factors or in pts w/o poor-prognosis factors but those that are prone to relapses
Length of the maintenance therapy remains to be established
However, majority of pts require long-term corticosteroids treatment to control asthma

<< Previous
Effect of interferon gamma-1b on survival in patients with...

Next >>
Exhaled breath condensate biomarkers in asbestos-related lung...